跳至主要内容
临床试验/NCT02270151
NCT02270151已完成3 期

Improving DEtection of Atrial fibriLlation in Primary Care With the MyDiagnostick

UMC Utrecht1 个研究点 分布在 1 个国家目标入组 16,000 人开始时间: 2014年11月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
UMC Utrecht
入组人数
16,000
试验地点
1
主要终点
Newly detected cases of AF

研究概览

简要总结

Atrial fibrillation (AF) is the most common arrhythmia and a common cause of stroke. AF can be asymptomatic and remain undiagnosed. Both the prevalence of AF and the proportion of strokes related to undetected AF increases with ageing. If AF is timely diagnosed and treated accordingly with anticoagulants, disabling strokes can be prevented. In order to help physicians in diagnosing atrial fibrillation, the MyDiagnostick was developed. It is a CE certified device that is safe, user friendly and easy to use. This device is capable of detecting or excluding AF within one minute by providing a registration of lead I of the ECG.

The investigators aim to perform a 2-arm cluster randomized diagnostic trial among patients aged 65 years and over who visit the general practice. In total the investigators will include 42 general practices of which they randomly assign 21 to the MyDiagnostick arm and 21 to the control arm. All persons aged 65 years and over who visit the general practice in the MyDiagnostick arm will be asked to hold the device every time they visit the surgery during one year.

The number of newly detected cases of AF with the diagnostic screening strategy with MyDiagnostick (MyDiagnostick arm) will be compared to care as usual (control arm). Also, the number of patients treated with anticoagulants according CHA2DS2-VASc score will be compared between both arms. Finally, the investigators will assess the number of major adverse cardiovascular events (MACE), intracerebral hemorrhages and other major hemorrhages, and all-cause mortality between the arms. End points will be assessed blinded to allocation.

The investigators hypothesise that the MyDiagnostick improves the diagnosis of atrial fibrillation in primary care and with accordingly treatment will reduce adverse outcomes.

详细描述

In a recent validation study performed in 200 patients visiting a cardiology outpatient clinic, the sensitivity was 100%, and specificity 96.4% with the MyDiagnostics as compared to a 12-lead ECG. Adequate comparison of this device with accordingly treatment with care as usual is needed before large scale implementation in the primary care setting can be advocated.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Screening
盲法
None

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Community dwelling persons visit the GP and aged 65 years of over

排除标准

  • Terminal illness of such severity that anticoagulation is considered to be not appropriate in case of newly detected atrial fibrillation
  • Acute situation in which GP should act instantly
  • Patients with a history of AF

结局指标

主要结局

Newly detected cases of AF

时间窗: One year

For our primary outcome the investigators will calculate the number of atrial fibrillation as detected with MyDiagnostick (MyDiagnostick arm) as compared to care as usual in primary care (control arm)

次要结局

  • Major cardiovascular events and all cause mortality(one year)
  • Adequate treatment of AF according the CHA2DS2-VASc score(one year)

研究者

发起方
UMC Utrecht
申办方类型
Other
责任方
Principal Investigator
主要研究者

Monika Hollander, MD, PhD

Monika Hollander, MD, PhD

UMC Utrecht

研究点 (1)

Loading locations...

相似试验

Improving DEtection of Atrial fibriLlation in... | 临床试验